You must be at least 61 years and 9 months, and want your benefits to start in no more than 4 months. Apply at ...

OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...

Democratic New York Gov. Kathy Hochul signed sweeping protections for abortion providers into law Monday and doubled down on ...

Robert F. Kennedy Jr. defended his prior public statements on a range of health policy issues in a fiery confirmation ...

RFK Jr goes before Senate for confirmation hearing to lead health agencies - Robert F Kennedy Jr is answering questions from ...

Trump imposed new tariffs on goods originating from its most immediate neighbors, Canada and Mexico, that would take effect ...

Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes between Zenrelia and Apoquel® (oclacitinib tablet) ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

With this acquisition, LipoVation becomes a wholly owned subsidiary of Revium Rx, aligning with the company’s renewed commitment to drug delivery innovation. Revium Rx is developing a portfolio of ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

President Donald Trump’s executive order imposing a 10% tariff on Chinese imports is l ikely to drive up the cost of generic ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.